Equities research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
NASDAQ BLPH opened at $0.04 on Friday. The firm has a market capitalization of $452,510.00, a PE ratio of -0.04 and a beta of 0.71. The company has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.05. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.10.
Bellerophon Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Bellerophon Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Breakout Alert: Qualcomm Just Hit The Rally Button
- How to Calculate Stock Profit
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
